Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/545—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/80—Vaccine for a specifically defined cancer
  • A61K2039/804—Blood cells [leukemia, lymphoma]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

• the present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed.
• DAA disorder-associated antigen
• the disclosure describes a molecular adjuvant for use in inducing or enhancing a subject’s immune response against a DAA, allowing for treatment of the disorder characterized by the DAA.
• a vaccine is a biological preparation that induces acquired immunity to a particular disease, providing protection (prophylactic vaccine) or aiding treatment (therapeutic vaccine).
• Vaccines typically have a basic composition that includes two principal components: one or more antigens derived from a causal agent (such as a neoplastic cell or a pathogenic microorganism), responsible for the specificity, and an adjuvant to enhance the composition
• Example treatment strategies include: metronomic chemotherapy, CD25 antibodies, CTLA4 antibodies, anti-GITR antibodies, anti-OX40, PD1 pathway modulation, Indoleamine 2,3-dioxygenase inhibitors, anti-LAG3, CCR4 antagonists, anti-FOXP3, blockade of TGF3, Listeriolysin O, blockade of adenosine-mediated immune suppression, anti-angiogenic molecules, folate receptor 4 antibodies, nicotinamide adenine dinucleotide, TLR modulation, and ICOS antibodies (reviewed in Batista-Duharte et al., Pharmacological Research 129 (2016) 237-250).
• Tregs and activated T-cells share several features and receptors, which explains the weak selectivity of some immunomodulators intended for specific Treg inhibition (Pere et al., Oncoimmunology 1 (3) (2012) 326-333; Ustun et al., Blood1 18 (19) (2011 ) 5084-5095).
• the present authors have studied the effects of administering CD25-ADCs in a number of different disease models, including models with CD25-ve tumor target cells. Their observations indicated an efficacy beyond what was expected for either of direct target cell killing by the ADC combined with the so-called‘bystander effect’ indirect cell killing, as described in WO/2017/083468. Building on these observations, the present authors reasoned that increased efficacy of ADCx25 arose from targeted cell-killing of AD25+ve regulatory immune cells, such as Tregs. That is, the present authors have determined that the CD25-ADCs described herein have applications as powerful and specific molecular adjuvants.
• the therapies described herein include those that induce or enhance a subject’s immune response.
• the therapies include treating a disorder by inducing or enhancing the immune response of a subject against an antigen associated with the disorder.
• the therapies described herein enhance or induce an immune response by targeting immune regulatory cells with a CD25-ADC. The targeting of immune regulatory cells in this manner allows for a reduction in the negative regulation of the subject’s immune responses to an existing or newly presented antigen.
• the therapies described herein enhance or induce an immune response by directly killing target cells through cytotoxic ADC binding to the target cells and/or, through a ‘bystander effect’, indirectly killing target cells in the proximity of cells that are directly bound by the cytotoxic ADC (see, for example, WO/2017/083468).
• the present disclosure provides a method of inducing or enhancing an immune response in a subject, the method comprising the step of administering a CD25- ADC to the subject.
• the immune response may be disorder-associated antigen (DAA) specific immune response, such as a CD8+ T cell response, a CD4+ T cell response, an antibody response, or a memory cell response.
• DAA disorder-associated antigen
• the present disclosure provides a method of treating or preventing a disorder a subject, wherein the disorder is characterized by a disorder-associated antigen (DAA), the method comprising administering a CD25-ADC to the subject.
• DAA disorder-associated antigen
• the CD25-ADC is administered in combination with a DAA.
• the DAA may be administered as part of a vaccine composition, optionally wherein the CD25-ADC is also part of the same vaccine composition.
• the CD25-ADC may administered in combination with the DAA or vaccine compostion, although they may be administered comcomitantly.
• the CD25-ADC is
• the immune-suppressive activity or size of a population of regulatory immune cells in the subject may be reduced by at least 90% before the DAA or vaccine composition is administered.
• the regulatory immune cells are Treg cells.
• the DAA may be tumour-associated antigen (TAA) or a pathogen-associated antigen (PAA).
• TAA tumour-associated antigen
• PAA pathogen-associated antigen
• the PAA is derived from a pathogen selected from the group consisting of a virus, bacterium, fungus, protozoa, parasite, prion protein, or protein aggregate.
• the subject has, is suspected of having, has been diagnosed with, or is at risk of, a disorder characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• the subject has been selected for treatment on the basis that the subject has, is suspected of having, has been diagnosed with, or is at risk of, a disorder characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• the disorder may be a proliferative disorder such as cancer.
• the proliferative disorder or cancer is a solid tumour, which may comprise or consist of CD25-ve neoplastic cells.
• the solid tumour may be associated with CD25+ve infiltrating cells, in some cases high levels of CD25+ve infiltrating cells.
• the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
• the proliferative disorder or cancer is lymphoma or leukaemia, such as Hodgkin’s Lymphoma; non-Hodgkin’s, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL) Marginal Zone B-cell lymphoma (MZBL); and leukemias, including Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
• the proliferative disorder or cancer may be associated with elevated levels of regulatory immune cells, such as Treg cells.
• the subject may be selected for treatment on the basis that the subject has received an adoptive cell transfer, such as a bone marrow transplant.
• the adoptive cell transfer may be an autologous cell transfer or an allogenic cell transfer, and may be a stem cell transfer and/or an immune cell transfer.
• the subject received the adoptive cell transfer at least 3 months prior to the administration of the CD25-ADC, such as at least 6 months, at least 12 months, at least 18 months, or at least 24 months prior to the
• the CD25-ADC may administered in combination with a cell therapy.
• the CD25- ADC is administered before the cell therapy, such as at least 7 days before the cell therapy.
• the immune-suppressive activity or size of a population of regulatory immune cells in the subject may be reduced by at least 90% before the cell therapy is administered.
• the regulatory immune cells are Treg cells.
• the cell therapy may comprise the administration of autologous cells, allogenic cells, stem cells, and/or immune cells.
• the administered cells are immune cells such as T-cells, Natural Killer (NK) cells, Natural Killer T-cell (NKT), Lymphokine-activated Killer (LAK) cells, or macrophages.
• the immune cells express a chimeric antigen receptor (CAR).
• CAR chimeric antigen receptor
• the immune cells are CAR T-cells, such as a 1 st generation CAR T-cell, a 2 nd generation CAR T-cell, a 3 rd generation CAR T-cell, a 4 th generation CAR T-cell, a TRUCK, a smart CAR, or an iCAR.
• the disclosure also provides an antibody-drug conjugate compound as disclosed herein for use in a method of treatmnent as disclosed herein.
• the disclosure also provides a composition or pharmaceutical composition comprising an antibody-drug conjugate compound as disclosed herein for use in a method of treatmnent as disclosed herein.
• the disclosure also provides a use of an antibody-drug conjugate compound as disclosed herein in the preparation of a medicament for use in a method of treatments as disclosed herein.
• the present disclosure provides a method of inducing or enhancing an immune response in a subject, the method comprising the step of
• the present disclosure provides a method of treating or preventing a disorder a subject, wherein the disorder is characterized by a disorder-associated antigen (DAA), the method comprising administering a CD25-ADC to the subject.
• DAA disorder-associated antigen
• the present disclosure provides method of inducing or enhancing an immune response in a subject.
• the immune response is a disorder-associated antigen (DAA) specific immune response. That is, the induced or enhanced immune response is elicited by and/or targeted to the DAA.
• DAA disorder-associated antigen
• the DAA-specific immune response is the activation and/or proliferation of CD8+ve T-cells (commonly referred to as T-Helper cells, or T h cells).
• DAA-specific T h cells will express a T-cell receptor (TCR) that specifically binds the DAA.
• TCR T-cell receptor
• the DAA-specific immune response is the activation and/or proliferation of CD4+ve T-cells (commonly referred to as cytotoxic T-cells, or T c cells).
• DAA- specific T c cells will express a T-cell receptor (TCR) that specifically binds the DAA.
• TCR T-cell receptor
• the DAA-specific immune response is the activation and/or proliferation of B-cells.
• DAA-specific B-cells will express a B-cell receptor (BCR) and/or secrete antibodies that specifically bind the DAA.
• BCR B-cell receptor
• the DAA-specific immune response is the secretion of antibodies that specifically bind the DAA.
• the DAA-specific immune response is the generation of memory cells.
• the memory cells may be memory T-cells or memory B-cells.
• the memory T-cells may be memory T h -cells or memory T c -cells.
• DAA-specific memory cells will express a surface receptor that specifically binds the DAA.
• the term‘inducing or enhancing an immune response’ as used herein refers to creating, or increasing the level of, the relevant immune response through administration of the CD25- ADC.
• the enhancement may be relative to, for example, a control subject or population of subjects who have not received the CD25-ADC.
• the existence or level of the immune response may be assessed by measuring the titer of a specific cell or molecule in a sample taken from a subject.
• the existence or level of a DAA-specific T c -cell response can be assessed by identifying and counting the relevant cells in a sample of peripheral blood taken from a subject.
• induction of an immune response means that following administration of the CD25-ADC the level of immune response is increased from am undetectable to a detectable level.
• an immune response is deemed to have ben induced if administration of the CD25-ADC is effective in preventing, ameliorating and/or treating a disorder characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• Prevention encompasses inhibiting or reducing the spread of the disorder or inhibiting or reducing the onset, development or progression of one or more of the symptoms associated with the disorder.
• Amelioration as used in herein may refer to the reduction of visible or perceptible disorder symptoms, or any other measurable manifestation of the disorder.
• enhancement of an immune response means that following administration of the CD25-ADC the level of the immune response is increased by at least 10%, such as by at least 20%, at least 30%, at least 40%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, or at least 500%.
• the level of immune response is assessed by determining the number of activated CD4+ve T-cell cells. In some embodiments the level of immune response is assessed by determining the size of certain cell populations, such as NK cells, monocyes, or dendritic cells). In some embodiments the level of immune response is assessed by determining the titre of a specific antibody or antibodies, for example the titre of an antibody or antiboides specific for a DAA.
• the immune response is induced or enhanced by administering the CD25-ADC to the subject in combination with a second immunostimulatory agent.
• the CD25-ADC may be administered to the subjecject in combination with a CD3/DAA bispecific T-cell engager (BiTE), an anti-CD47 therapeutic, a PD-1 inhbitor, a PDL-1 inhbitor, a GITR agonist, an 0X40 agonist, or a CTLA-1 antagonist,
• the second immunostimulatory agent used as a monotherapy does not induce a significant immune response in the subject.
• the present disclosure provides a method of treating or preventing a disorder a subject, wherein the disorder is characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• Disorders characterised by a DAA include proliferative diseases such as cancer, wherein neoplastic cells express one or more antigen that is either (i) not expressed on
• non-neoplastic cells or more usually (ii) expressed at ha higher level on neoplastic cells than on non-neoplastic cells.
• Disorders characterised by a DAA also include diseases caused by a pathogen, wherein the pathogen is (or expresses) an antigen.
• diseases caused by a pathogen wherein the pathogen is (or expresses) an antigen.
• the efficacy of the treatment methods described herein is believed to arise from the induction and/or enhancement of the subject’s immune response against the DAA.
• This induction and/or enhancement is believed to be due to the administration of the CD25-ADC reducing the immune-suppressive activity of a population of immune regulatory cells (such as CD25+ve T reg cells).
• the reduction in regulatory-cell immune-suppression allows for the induction and/or enhancement of the immune response against the DAA.
• Treg cells Tregs are identified by surface expression of CD4+ve / CD25 high / CD127 l0W/ [33] and form two main subsets: natural Tregs (nTregs), which are thymus-derived, and induced, adaptive or peripheral Tregs (pTregs), which are derived from naive CD4+T cells under a variety of conditions (Curotto de Lafaille et al., Immunity 30 (2009)626-635-).
• Tregs have immunosuppressive activity, with the more important effector T cells (Teffs) that are suppressed by Tregs being Th1 (control of infections and tumors), Th2 (effectors against extra-cellular parasites, including helminths), Th17 (play an important role in pathogen clearance at mucosal surfaces, are effective against pathogenic fungi and are also involved in different inflammatory process) and CTLs (cytotoxic T cells).
• Treg-mediated suppression can be accomplished in two ways :by cell-cell contact or by means of soluble mediators and cytokines (paracrine signaling).
• immunoregulatory cytokines such as TGF3, IL-10,and IL-35;
• metabolic interruption including inhibition of proliferative response via the IL-2 receptor, cAMP-mediated metabolic inhibition, tryptophane depletion and
• the DAA is not administered in combination with the DAA. This may be the case in embodiments where, for example, the DAA is already present in the subject when the CD25-ADC is administered.
• the subject may already have a proliferative disease characterised by a neoplasm whose cells express the DAA. In these cases the subject’s immune response against the DAA may be suppressed or attenuated by a population of immune regulatory cells either globally, or in the neoplasm microenvironment.
• a number of proliferative disorders have been reported to be associated with an increased number of immune regulatory cells such as T reg cells.
• immune regulatory cells such as T reg cells.
• reducing the immune- suppressive activity of immune regulatory cells allows for the effective‘unmasking’ of the DAA-expressing neoplastic cells and their attack by the subject’s immune system.
• the administration of the CD25-ADC allows for the effective treatment of a broad range of disorders.
• the DAA is administered in combination with a CD25-ADC.
• the term“DAA” encompasses both, (1 ) the antigen itself in the form it is recognised by the subject immune system, and (2) molecules which stimulate an immune response specific to the DAA.
• the p24 polypeptide itself is a DAA of type (1 ).
• An immune response against the p24 protein may also be generated by administering to the subject a suitable vaccine vector containing a nucleotide encoding the p24 protein; accordingly, the nucleotide encoding p24 is a DAA of type (2).
• the DAA is a“self” antigen.
• TAAs tumour associated antigens
• many tumour associated antigens are self antigens which are expressed at higher levels on neoplastic cells.
• the DAA is a“non-self antigen.
• many antigens expressed by pathogenic microorganisms are non-self antigens.
• a DAA may be administered as part of a vaccine composition.
• the vaccine composition comprises a therapeutically effective amount of the DAA.
• Therapeutically effective amount refers to an amount of DAA that is effective for preventing, ameliorating and/or treating a disorder characterized by the DAA.
• Prevention encompasses inhibiting or reducing the spread of the disorder or inhibiting or reducing the onset, development or progression of one or more of the symptoms associated with the disorder.
• Amelioration as used in herein may refer to the reduction of visible or perceptible disorder symptoms or any other measurable manifestation of the disorder.
• Suitable types of vaccine composition include:
• vectored vaccines such as viral vectored vaccine, bacterial vectored vaccine, or plasmid DNA
• non-vectored vaccines such as those comprising a naked protein DAA.
• vectored vaccines is well known in the art and includes plasmid DNA
• poxviruses such as MV A, replicating vaccinia, fowlpox, avipox, also of adenoviruses including nonhuman primate adenoviruses, of alphaviruses, of vesicular stomatitis virus, and bacterial vectors such as Salmonella, Shigella and BCG.
• the vectored vaccine may contain, or contain a nucleic acid encoding, a recombinant protein DAA.
• the recombinant DAA may be expressed in a viral vector.
• viral vectors examples include vaccinia virus vectors such as MVA or NYVAC, avipox vectors such as fowlpox or canarypox (eg. ALVAC), vectors based on herpes virus, and vectors based on Venezuelan equine encephalitis virus (VEE).
• vaccinia virus vectors such as MVA or NYVAC
• avipox vectors such as fowlpox or canarypox (eg. ALVAC)
• VEE Venezuelan equine encephalitis virus
• bacterial vectors include recombinant BCG and recombinant Salmonella and Salmonella transformed with plasmid DNA.
• non-vectored vaccines include carrier molecules such as lipid-tailed peptides known as lipopeptides, peptides fused to carrier proteins such as KLH either as fusion proteins or by chemical linkage, and antigens modified with a targeting tag, for example C3d or C4b binding protein. Alternatively, naked antigens may be administered.
• the vaccine compositions further comprise one or more adjuvants. Adjuvants are known in the art to further increase the immune response to an applied antigenic determinant. The terms“adjuvant” and“immune stimulant” are used
• an adjuvant is used to enhance an immune response to a DAA.
• suitable adjuvants include aluminium salts such as aluminium hydroxide and/or aluminium phosphate; oil-emulsion compositions (or oil-in-water compositions), including squalene-water emulsions, such as MF59 (see e.g. WO 90/14837); saponin formulations, such as for example QS21 and Immunostimulating Complexes (ISCOMS) (see e.g. U.S. Pat. No. 5,057,540; WO 90/03184, WO 96/1171 1 , WO 2004/004762, WO 2005/002620);
• ICOMS Immunostimulating Complexes
• bacterial or microbial derivatives examples of which are monophosphoryl lipid A (MPL), 3-0- deacylated MPL (3dMPL), CpG-motif containing oligonucleotides, ADP-ribosylating bacterial toxins or mutants thereof, such as E. coli heat labile enterotoxin LT, cholera toxin CT, and the like; eukaryotic proteins (e.g. antibodies or fragments thereof (e.g. directed against the antigen itself or CD1a, CD3, CD7, CD80) and ligands to receptors (e.g. CD40L, GMCSF, GCSF, etc), which stimulate immune response upon interaction with recipient cells.
• MPL monophosphoryl lipid A
• 3dMPL 3dMPL
• CpG-motif containing oligonucleotides such as E. coli heat labile enterotoxin LT, cholera toxin CT, and the like
• eukaryotic proteins
• the vaccine compositions comprise aluminium as an adjuvant, e.g. in the form of aluminium hydroxide, aluminium phosphate, aluminium potassium phosphate, or combinations thereof, in concentrations of 0.05-5 mg, e.g. from 0.075-1.0 mg, of aluminium content per dose.
• Administration of the vaccine compositions can be performed using standard routes of administration.
• Non-limiting embodiments include parenteral administration, such as intradermal, intramuscular, subcutaneous, transcutaneous, or mucosal administration, e.g. intranasal, oral, and the like.
• a composition is administered by intramuscular injection.
• the skilled person knows the various possibilities to administer a composition, e.g. a vaccine in order to induce an immune response to the antigen(s) in the vaccine.
• a composition is administered intramuscularly.
• the DAA or vaccine compositions may be administered, either as prime, or as boost, in a homologous or heterologous prime-boost regimen. If a boosting vaccination is performed, typically, such a boosting vaccination will be administered to the same subject at a time between one week and one year, preferably between two weeks and four months, after administering the composition to the subject for the first time (which is in such cases referred to as‘priming vaccination’).
• the administration comprises a prime and at least one booster administration.
• the DAA may be administered to the subject before the CD25-ADC, concomitantly with the CD25-ADC, or after the CD25-ADC
• the CD25-ADC is administered before the DAA.
• the CD25-ADC may be administered 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours before the DAA.
• the CD25-ADC may be administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days before the DAA.
• the CD25-ADC is administered at least 1 day before the DAA, even more preferably at least 2 days before the DAA.
• the immune-suppressive activity of a population of immune regulatory cells is reduced before the DAA is administered to the subject. In some embodiments the reduction in the immune-suppressive activity of the immune regulatory cell population is achieved by killing a proportion of the population. In some embodiments the reduction in the immune-suppressive activity of the immune regulatory cell population is achieved by inhibiting the immune-suppressive activity of a proportion of the regulatory cell population without killing the cells.
• the immune regulatory cells may be myeloid-derived suppressor cells (MDSCs),
• MSCs mesenchymal stromal cells
• Type II NKT cells Type II NKT cells
• Treg cells any other immune regulatory immune cells as defined herein.
• Treg cells are Treg cells.
• the term“Treg” cells as used herein refers to regulatory T-cells. This cell population may be identified by the following pattern of surface-marker expression: CD4+ve, CD25 high , CD127
• the immune-suppressive activity of a population of immune regulatory cells is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 70%, at least 90%, at least 95%, or at least 98% before the DAA is administered to the subject.
• the reduction is measured relative to levels in the same subject prior to the administration of the CD25-ADC.
• the immune-suppressive activity of a population of immune regulatory cells is assessed by measuring the level of inhibitory cytokines such as IL-10, TGF3, or IL-35 (see Bettini et al., Current opinion in immunology. 2009;21 (6):612-618). In some embodiments the immune-suppressive activity of a population of immune regulatory cells is assessed by measuring the expression of specific genes such as LAYN, MADEH1 , or CCR8 (see de Simone et al., Immunity. 2016 Nov 15; 45(5): 1 135-1 147).
• the size of a population of immune regulatory cells is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 70%, at least 90%, at least 95%, or at least 98% before the DAA is administered to the subject.
• the reduction in population size is measured relative to levels in the same subject prior to the administration of the CD25-ADC.
• the population of immune regulatory cells is measured systemically, for example by using FACS on a representative sample such as whole blood, bone-marrow, lymph-nodes, spleen, peyer-plaques, or tonsils.
• the population of immune regulatory cells is measured locally, for example in a sample taken from a tumour or the tumour microenvironment.
• the local population of immune regulatory cells may be measured by, for example, FACS, immunohisochemistry or immunofluorescence of tissue sections.
• techniques such as RNAscope® may be used on tissue sections to quantify immune regulatory cells in biopsies. Local measurement of cell population is preferred in situations where local measurement is possible (for example, for solid tumours).
• the CD25-ADC is administered concomitantly with the DAA.
• the dose of CD25-ADC administered is about 20 pg/kg to 80 pg/kg, such as about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 pg/kg.
• the type I transmembrane protein CD25 is present on activated T- and B- cells, some thymocytes, myeloid precursors, and oligodendrocytes. On activated T-cells, it forms heterodimers with the beta- and gamma subunits (CD122 and CD132), thus comprising the high-affinity receptor for IL-2. This ligand represents a survival factor for activated T-cells, as removal of IL-2 leads to immediate death of these cells.
• CD25 is physiologically expressed in early developmental stages of late pro-B and pre-B cells. Malignancies arising from this stage of B-cell differentiation may thus also express CD25. Mast cell lesions are also positive for CD25 which is thus considered as a key diagnostic criterion for determination of systemic mastocytosis.
• Hodgkin lymphomas CD25 is reported to be not expressed in Hodgkin-/Reed-Sternberg cells in nodular lymphocyte predominance Hodgkin lymphoma (NLPHL), whereas the same cell type expresses CD25 at varying levels in classical Hodgkin’ lymphomas of mixed cellularity type. The general expression levels are reported to be lower than in tumor infiltrating lymphocytes (TILs), which may result in problems demonstrating CD25 tumor cells in these cases (Levi et al., Merz et al, 1995).
• TILs tumor infiltrating lymphocytes
• B- and T-cell-derived subtypes of non-Hodgkin-lymphomas i.e. B-cell chronic lymphatic leukemia, hairy cell leukemia, small cell lymphocytic lymphoma/chronic lymphocytic leukemia as well as adult T- cell leukemia/lymphoma and anaplastic large cell lymphoma.
• CD25 may be localised to the membrane, with some expression observed in the cytoplasm. Soluble CD25 may also be observed outside of cells, such as in serum.
• ADC antibody-drug conjugates
• cytotoxic or cytostatic agents i.e. drugs to kill or inhibit tumour cells in the treatment of cancer
• cytotoxic or cytostatic agents i.e. drugs to kill or inhibit tumour cells in the treatment of cancer
• systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells
• CD25-ADC refers to an ADC in which the antibody component is an anti-CD25 antibody.
• the CD25-ADC has the structure defined in the following paragraphs:
• L is an antibody (Ab) which is an antibody that binds to CD25;
• R 12 is selected from the group consisting of:
• R 21 , R 22 and R 23 are independently selected from H, C 1-3 saturated alkyl, C 2-3 alkenyl, C 2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R 12 group is no more than 5; 25b
• R 25a and R 25b are H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy;
• R 24 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
• R 12 is , where R 26a and R 26b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from Ci -4 alkyl amido and Ci -4 alkyl ester; or, when one of R 26a and R 26b is H, the other is selected from nitrile and a Ci -4 alkyl ester;
• R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR’, nitro, MesSn and halo;
• R and R’ are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups;
• R 7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR’, nitro, MesSn and halo;
• R" is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR N2 (where R N2 is H or Ci -4 alkyl), and/or aromatic rings, e.g. benzene or pyridine;
• Y and Y’ are selected from O, S, or NH;
• R 6 , R 7 , R 9 are selected from the same groups as R 6 , R 7 and R 9 respectively;
• R L is a linker for connection to the antibody (Ab);
• R 11a is selected from OH, OR A , where R A is Ci -4 alkyl, and SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
• R 20 and R 21 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
• R 20 is selected from H and R c , where R c is a capping group
• R 21 is selected from OH, OR A and SO z M;
• R 2 is selected from the group consisting of:
• R 11 , R 1 and R 13 are independently selected from H, C 1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R 2 group is no more than 5;
• R 15a and R 15b are H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and
• R 14 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-: alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
• R 2 is R 16 " where R 1ba and R 1bb are independently selected from H, F, C 1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from Ci -4 alkyl amido and Ci -4 alkyl ester; or, when one of R 16a and R 16b is H, the other is selected from nitrile and a Ci -4 alkyl ester;
• R 22 is of formula Ilia, formula lllb or formula I lie:
• A is a C 5-7 aryl group
• Q 1 is a single bond
• Q 2 is selected from a single bond and -Z-(CH2) n -, where Z is selected from a single bond, O, S and NH and n is from 1 to 3;
• R C1 , R C2 and R C3 are independently selected from H and unsubstituted C1-2 alkyl; l llc
• R N is selected from the group comprising H and C1-4 alkyl
• R L2’ is a linker for connection to the antibody (Ab);
• R 10 and R 11 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
• R 10 is H and R 11 is selected from OH, OR A and SO z M;
• R 30 and R 31 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
• R 30 is H and R 31 is selected from OH, OR A and SO z M.
• R 21 The conjugate according to any one of statements 18 to 20, wherein one of R 21 , R 22 and R 23 is H, with the other two groups being selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl.
• R 2 , and R 16a and R 16b are both methyl.
• R 16a and R 16b are H, and the other is selected from Ci -4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted.
• G 2 is a terminating group
• L 3 is a covalent bond or a cleavable linker L 1
• R C1 , R C2 and R C3 are independently selected from H and methyl.
• L 1 is a cleavable linker
• A is a connecting group connecting L 1 to the antibody
• asterisk indicates the point of attachment to the PBD
• the wavy line indicates the point of attachment to the linker L 1
• n is 0 to 3.
• the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.
• the antibody comprises:
• VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8.
• the conjugate according to statement 108 comprising a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.
• anti-CD25-ADC may include any embodiment described in WO 2014/057119.
• the ADC has the chemical structure:
• the antibody may comprise a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5.
• the antibody component of the anti-CD25-ADC is an antibody comprising: a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5.
• the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.
• the antibody may further comprise: a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8.
• the antibody further comprises a VL domain having the sequence according to SEQ ID NO. 2.
• the antibody comprises a VH domain and a VL domain, the VH and VL domains having the sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2.
• the VH and VL domain(s) may pair so as to form an antibody antigen binding site that binds CD25.
• the antibody is an intact antibody comprising a VH domain and a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 and SEQ ID NO. 2.
• the antibody is a fully human monoclonal lgG1 antibody, preferably lgG1 ,K.
• the antibody is the AB12 antibody described in WO 2004/045512 (Genmab A/S).
• the antibody is an antibody as described herein which has been modified (or further modified) as described below.
• the antibody is a humanised, deimmunised or resurfaced version of an antibody disclosed herein.
• ADCX25 / ADCT-301 / Camidanlumab Tesirine The most preferred anti-CD25-ADCs for use with the aspects of the present disclosure is ADCX25 / ADCT-301 / Camidanlumab Tesirine; the structure of ADCx25 is described herein below.
• ADCx25 is an antibody drug conjugate composed of a human antibody against human CD25 attached to a pyrrolobenzodiazepine (PBD) warhead via a cleavable linker.
• the mechanism of action of ADCX25 depends on CD25 binding.
• the CD25 specific antibody targets the antibody drug conjugate (ADC) to cells expressing CD25.
• ADC antibody drug conjugate
• the ADC internalizes and is transported to the lysosome, where the protease sensitive linker is cleaved and free PBD dimer is released inside the target cell.
• the released PBD dimer inhibits transcription in a sequence-selective manner, due either to direct inhibition of RNA polymerase or inhibition of the interaction of associated transcription factors.
• the PBD dimer produces covalent crosslinks that do not distort the DNA double helix and which are not recognized by nucleotide excision repair factors, allowing for a longer effective period (Hartley 201 1 ).
• Antibody AB12 (fully human monoclonal lgG1 , K antibody with the VH and VL sequences SEQ ID NO. 1 and SEQ ID NO. 2, respectively, also known as HuMax-TAC). It is synthesised as described in WO 2014/0571 19 (Conj AB12-E) and typically has a DAR (Drug to Antibody Ratio) of 2.0+/-0.3.
• The“first target protein” (FTP) as used herein is preferably CD25.
• binds CD25 is used to mean the antibody binds CD25 with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no. CAA76847.1 Gl:3336842, record update date: Jan 7, 201 1 02:30 PM).
• BSA Bovine Serum Albumin
• the antibody binds CD25 with an association constant (K a ) at least 2, 3, 4 , 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10 4 , 10 5 or 10 6 -fold higher than the antibody’s association constant for BSA, when measured at physiological conditions.
• the antibodies of the disclosure can bind CD25 with a high affinity.
• the antibody can bind CD25 with a KD equal to or less than about 10 6 M, such as equal to or less than one of 1 x 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10- 13 or 10 14 .
• CD25 polypeptide corresponds to Genbank accession no. NP_000408, version no. NP_000408.1 Gl:4557667, record update date: Sep 09, 2012 04:59 PM.
• the nucleic acid encoding CD25 polypeptide corresponds to Genbank accession no. NM_000417, version no. NM_000417.2 Gl:269973860, record update date: Sep 09, 2012 04:59 PM.
• CD25 polypeptide corresponds to Uniprot/Swiss-Prot accession No. P01589. Therapeutic uses of CD25 ADCs
• an Antibody Drug Conjugate comprising an anti-CD25 antibody (herein termed a CD25-ADC) in the treatment of, for example, cancer is known - see, for example, WO2014/0571 19, WO2016/083468, and WO2016/166341.
• the therapies described herein are combined with cell therapy, such as CAR T- cell therapy.
• cell therapy such as CAR T- cell therapy.
• the administration of a CD25-ADC is used to reduce the immune-suppressive activity of a population of immune regulatory cells, to allow for greater efficacy of a cell therapy administered in combination with the CD25-ADC.
• the CD25-ADC is administered before the cell therapy.
• the CD25-ADC is administered before the cell therapy.
• CD25-ADC may be administered 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours before the cell therapy.
• the CD25-ADC may be administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days , 9 days , 10 days , 11 days , 12 days , 13 days , or 14 days before the cell therapy.
• the gap between CD25-ADC and cell therapy administrations is sufficient for the systemic level of CD25-ADC to drop to 25% or less of the administered dose (i.e. 2 half-lives of the CD25-ADC) before the cell therapy is administered. This is so the cells administered during the cell therapy are not exposed to high levels of the CD25-ADC.
• the CD25-ADC is administered at least 7 days before the cell therapy.
• the immune-suppressive activity of a population of immune regulatory cells is reduced before the cell therapy is administered to the subject. In some embodiments the reduction in the immune-suppressive activity of the immune regulatory cell population is achieved by killing a proportion of the population. In some embodiments the reduction in the immune-suppressive activity of the immune regulatory cell population is achieved by inhibiting the immune-suppressive activity of a proportion of the regulatory cell population without filling the cells.
• the immune regulatory cells may be myeloid-derived suppressor cells (MDSCs), mesenchymal stromal cells (MSCs), Type II NKT cells, Treg cells, or any other immune regulatory immune cells as defined herein.
• MDSCs myeloid-derived suppressor cells
• MSCs mesenchymal stromal cells
• Type II NKT cells Type II NKT cells
• Treg cells or any other immune regulatory immune cells as defined herein.
• Treg cells are Treg cells.
• the term“Treg” cells as used herein refers to regulatory T-cells. This cell population may be identified by the following pattern of surface-marker expression: CD4+ve, CD25 high , CD127
• the immune-suppressive activity of a population of immune regulatory cells is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 70%, at least 90%, at least 95%, or at least 98% before the cell therapy is administered to the subject.
• the reduction is measured relative to levels in the same subject prior to the administration of the CD25-ADC.
• the immune-suppressive activity of a population of immune regulatory cells is assessed by measuring the level of inhibitory cytokines such as IL-10, TGF3, or IL-35 (see Bettini et al., Current opinion in immunology. 2009;21 (6):612-618).
• the immune-suppressive activity of a population of immune regulatory cells is assessed by measuring the expression of specific genes such as LAYN, MADEH1 , or CCR8 (see de Simone et al., Immunity. 2016 Nov 15; 45(5): 1 135-1 147).
• the size of a population of immune regulatory cells is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 70%, at least 90%, at least 95%, or at least 98% before the cell therapy is
• the reduction in population size is measured relative to levels in the same subject prior to the administration of the CD25-ADC.
• the population of immune regulatory cells is measured systemically, for example by using FACS on a representative sample such as whole blood.
• the population of immune regulatory cells is measured locally, for example in a sample taken from a tumour or the tumour microenvironment.
• the local population of immune regulatory cells may be measured by, for example, immunofluorescence of tissue sections.
• the CD25-ADC is administered concomitantly with the cell therapy.
• the cell therapy comprises the administration of autologous cells. In some embodiments the cell therapy comprises the administration of allogenic cells.
• the cell therapy comprises the administration of stem cells.
• the cell therapy comprises the administration of immune cells.
• the immune cells may be cytotoxic effector cells.
• the immune cells may be T-cells, Natural Killer (NK) cells, Natural Killer T-cell (NKT), Lymphokine-activated Killer (LAK) cells, or
• the immune cells are‘CAR immune cells’, as defined herein below.
• CAR immune cell Conventional immune cells may be genetically modified such that they express a CAR as described and referenced herein below.
• An immune cells so modified is described herein as “CAR immune cell” and is suitable for use in the cell therapies as described herein.
• CARs may be expressed in a number of different immune cells. Suitable immune cells for expressing a CAR include T-cells - such as cytotoxic T-cells and helper T-cells - as well as Natural Killer (NK) cells. In preferred cases, the CAR immune cell is a T-cell. In these cases, the CAR expressing T-cell is termed here in as a“CAR T-cell”.
• Chimeric antigen receptors has its normal meaning in the art, including The current state of the art with respect to CARs is reviewed in for example: Hartmann, J., et al., EMBO Mol. Med., 2017, Vol. 9, Issue 9, pp. 1183-1197 // Brudno, JN.
• CARs are composed of an extracellular binding domain, a hinge region, a transmembrane domain, and one or more intracellular signaling domains.
• Single-chain variable fragments (scFvs) derived from tumor antigen-reactive antibodies are typically used as extracellular binding domains.
• All CARs harbor the CD3epsilon chain domain as the intracellular signaling domain.
• the extracellular binding domain of a CAR is capable of recognizing and binding to a specific antigen.
• a target antigen generally has numerous binding sites, also called epitopes, recognized by Complementarity Determining Regions (CDRs) on multiple CARs.
• CDRs Complementarity Determining Regions
• Each CAR that specifically binds to a different epitope has a different structure.
• one antigen may have more than one corresponding CAR.
• a CAR may comprise a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof (eg. An scFv), such targets including but not limited to, cancer cells.
• a target of interest e.g. An scFv
• targets including but not limited to, cancer cells.
• second- and third-generation CARs also contain one or more co-stimulatory domains, like CD28 and/or 4-1 BB. These co-stimulatory domains improve proliferation, cytokine secretion, resistance to apoptosis, and in vivo persistence of cells expressing the CARs. Third-generation CARs exhibit improved effector functions and in vivo persistence as compared to second-generation CARs.
• Fourth-generation CARs so-called TRUCKS or armored CARs, combine the expression of a second-generation CAR with factors that enhance anti-tumoral activity, such as cytokines, costimulatory ligands, or enzymes that degrade the extracellular matrix of solid tumors (Chmielewski & Abken, 2015, Expert Opin Biol Ther 15, pp.1145 - 1 154).
• factors that enhance anti-tumoral activity such as cytokines, costimulatory ligands, or enzymes that degrade the extracellular matrix of solid tumors (Chmielewski & Abken, 2015, Expert Opin Biol Ther 15, pp.1145 - 1 154).
• CARs include so-called smart T cells which are either equipped with a suicide gene or include synthetic control devices are under non-clinical and clinical investigation (Zhang & Xu, ibid.).
• the CD25-ADCs decribed herein are administered in combination with a checkpoint inhibitor.
• the CD25-ADC may be administered before the checkpoint inhibitor, simultaneous with the checkpoint inhibitor, or after the checkpoint inhibitor.
• the checkpoint inhibitor may be, for example, a PD1 antagonist, a PD-L1 antagonist, a GITR agonist, an 0X40 agonist, or a CTLA-4 antagonist
• Programmed death receptor I is an immune-inhibitory receptor that is primarily expressed on activated T and B cells. Interaction with its ligands has been shown to attenuate T-cell responses both in vitro and in vivo. Blockade of the interaction between PD1 and one of its ligands, PD-L1 , has been shown to enhance tumor-specific CD8+ T-cell immunity and may therefore be helpful in clearance of tumor cells by the immune system.
• PD1 (encoded by the gene Pdcdl) is an Immunoglobulin superfamily member related to CD28, and CTLA-4. PD1 has been shown to negatively regulate antigen receptor signalling upon engagement of its ligands (PD-L1 and/or PD-L2). The structure of murine PD1 has been solved as well as the co-crystal structure of mouse PD1 with human PD-L1
• PD1 and like family members are type I transmembrane glycoproteins containing an Ig Variable-type (V-type) domain responsible for ligand binding and a cytoplasmic tail that is responsible for the binding of signaling molecules.
• the cytoplasmic tail of PD1 contains two tyrosine-based signaling motifs, an ITIM (immunoreceptor tyrosine- based inhibition motif) and an ITSM (immunoreceptor tyrosine-based switch motif).
• PD1 on tumor infiltrating lymphocytes
• PD-L1 on tumor cells
• Such tissues include cancers of the lung, liver, ovary, cervix, skin, colon, glioma, bladder, breast, kidney, esophagus, stomach, oral squamous cell, urothelial cell, and pancreas as well as tumors of the head and neck (Brown, J. A., et al., (2003) J Immunol. I 70: I257-I266; Dong H., et al., (2002) Nat. Med.
• Antibody blockade effectively promoted tumor reactive CD8+ T cell infiltration into the tumor resulting in the up-regulation of anti-tumor effectors including IFN gamma, granzyme Band perforin. Additionally, the authors showed that PD1 blockade can be effectively combined with chemotherapy to yield a synergistic effect. In another study, using a model of squamous cell carcinoma in mice, antibody blockade of PD1 or PD-L1 significantly inhibited tumor growth (Tsushima, F., et al., (2006) Oral Oneal. 42: 268-274).
• PD1 antagonist means any chemical compound or biological molecule that stimulates an immune reaction through inhibition of PD1 signalling.
• samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples treated with an inactive control molecule. Control samples are assigned a relative activity value of 100%.
• Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 20%.
• Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.
• an ADC which targets a first target protein (FTP) with PD1 inhibitors is advantageous, because on the one hand, the ADC will directly kill the FTP positive tumor cells, while on the other hand the PD1 inhibitor will engage the patient’s own immune system to eliminate the cancer cells.
• FTP first target protein
• the PD1 inhibitor will engage the patient’s own immune system to eliminate the cancer cells.
• FTP(+) tumor cells FTP negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of CD25(+) cells.
• the ADC will directly kill the tumor cells.
• PD1 programmed cell death protein 1
• TILs tumour infiltrating lymphocytes
• PD1 The major function of PD1 is to limit the activity of T-cells at the time of an anti-inflammatory response to infection and to limit autoimmunity. PD1 expression is induced when T-cells become activated, and binding of one of its own ligands inhibits kinases involved in T-cell activation. Hence, in the tumor environment this may translate into a major immune resistance, because many tumours are highly infiltrated with TReg cells that probably further suppress effector immune responses. This resistance mechanism is alleviated by the use of PD1 inhibitors in combination with the ADC.
• PD1 antagonists suitable for use as secondary agents in the present disclosure include: a) a PD1 antagonist which inhibits the binding of PD1 to its ligand binding partners. b) a PD1 antagonist which inhibits the binding of PD1 to PD- L1.
• a PD1 antagonist which inhibits the binding of PD-1 to PDL2.
• a PD1 antagonist which inhibits the binding of PD-1 to both PDLI and PDL2.
• Specific PD1 antagonists suitable for use as secondary agents in the present disclosure include:
• pembrolizumab brand name Keytruda
• PD1 polypeptide corresponds to Genbank accession no. AAC51773, version no. AAC51773.1 , record update date: Jun 23, 2010 09:24 AM.
• the nucleic acid encoding PD1 polypeptide corresponds to Genbank accession no. U64863, version no. U64863.1 , record update date: Jun 23, 2010 09:24 AM.
• PD1 polypeptide corresponds to Uniprot/Swiss-Prot accession No. Q15116.
• PD-L1 antagonist means any chemical compound or biological molecule that stimulates an immune reaction through inhibition of PD-L1 signalling.
• samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples treated with an inactive control molecule. Control samples are assigned a relative activity value of 100%.
• Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 20%.
• Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.
• ADC which targets a first target protein (FTP) positive lymphomas and leukemias
• FTP target protein
• target negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of FTP(+) cells.
• the ADC will directly kill the tumor cells.
• the resulting release of tumor associated antigens from cells that are killed with the PBD dimer will trigger the immune system, which will be further enhanced by the use of programmed cell death protein 1 ligand inhibitors (PD-L1 , aka B7-H1 or CD274 ).
• PD-L1 is commonly upregulated on the tumour cell surface from many different human tumours. Interfering with the PD1 ligand expressed on the tumor will avoid the immune inhibition in the tumor microenvironment and therefore blockade of the PD1 pathway using PDL1 inhibitors may enhance antitumour immune responses against the antigens released from the tumors killed by the ADC.
• an ADC which targets a first target protein (FTP) with PD1 inhibitors is advantageous, because on the one hand, the ADC will directly kill the FTP positive tumor cells, while on the other hand the PD1 inhibitor will engage the patient’s own immune system to eliminate the cancer cells.
• FTP first target protein
• the PD1 inhibitor will engage the patient’s own immune system to eliminate the cancer cells.
• FTP(+) tumor cells FTP negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of CD19(+) or CD22 (+) cells.
• the ADC will directly kill the tumor cells.
• PD-L1 antagonists suitable for use as secondary agents in the present disclosure include PD-L1 antagonists that:
• (e) are anti-PD-L1 antibodies.
• Specific PD-L1 antagonists suitable for use as secondary agents in the present disclosure include:
• VH CDR1 DYGFS
• VH CDR2 WITAYNGNTNYAQKLQG
• VH CDR3 DYFYGMDV
• VL CDR1 RASQSVSSYLV
• VL CDR2 DAS N RAT
• VL CDR3 QQRSNWPRT ii.
• Antibody having:
• VH CDR1 TYAIS
• VH CDR2 GIIPIFGKAHYAQKFQG
• VH CDR3 KFHFVSGSPFGMDV
• VL CDR1 RASQSVSSYLA
• VL CDR2 DAS N RAT
• VL CDR3 QQRSNWPT
• Antibody having:
• VH CDR1 SYDVH
• VH CDR2 WLHADTGITKFSQKFQG
• VH CDR3 ERIQLWFDY
• VL CDR1 RASQGISSWLA
• VL CDR2 AASSLQS
• VL CDR3 QQYNSYPYT c) durvalumab/MEDI4736
• PD-L1 polypeptide corresponds to Genbank accession no. AAF25807, version no. AAF25807.1 , record update date: Mar 10, 2010 10:14 PM.
• the nucleic acid encoding PD1 polypeptide corresponds to Genbank accession no. AF177937, version no. AF177937.1 , record update date: Mar 10, 2010 10:14 PM.
• PD1 polypeptide corresponds to Uniprot/Swiss-Prot accession No. Q9NZQ7.
• glucose-induced TNF receptor (abbreviated herein as
• GITR also known as TNF receptor superfamily 18 (TNFRSF18, CD357), TEASR, and 312C2, as used herein, refers to a member of the tumor necrosis factor/nerve growth factor receptor family.
• GITR is a 241 amino acid type I transmembrane protein characterized by three cysteine pseudo-repeats in the extracellular domain and specifically protects T-cell receptorinduced apoptosis, although it does not protect cells from other apoptotic signals, including Fas triggering, dexamethasone treatment, or UV irradiation (Nocentini, G., et al. (1997) Proc. Natl. Acad. Sci. USA 94:6216-622).
• GITR activation increases resistance to tumors and viral infections, is involved in autoimmune/inflammatory processes and regulates leukocyte extravasation (Nocentini supra; Cuzzocrea, et al. (2004) J Leukoc. Biol. 76:933-940; Shevach, et al. (2006) Nat. Rev. Immunol. 6:613-618; Cuzzocrea, et al. (2006) J Immunol. I 77:631-641; and Cuzzocrea, et al. (2007) FASEB J 21 :l I 7-129).
• agonist GITR antibody, DTA-I was combined with an antagonist CTLA-4 antibody, and showed synergistic results in
• hGITR human GITR
• GITR agonist means any chemical compound or biological molecule that stimulates an immune reaction through activation of GITR signalling. Also contemplated are soluble GITR- L proteins, a GITR binding partner. To examine the extent of enhancement of, e.g., GITR activity, samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples treated with an inactive control molecule. Control samples are assigned a relative activity value of 100%.
• Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 20%.
• Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.
• an ADC which targets a first target protein (FTP) positive lymphomas and leukemias with GITR agonists is advantageous, because on the one hand the ADC will directly kill the FTP positive tumor cells, while on the other hand the GITR agonist will engage the patient’s own immune system to eliminate the cancer cells.
• FTP target protein
• target negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of FTP(+) cells.
• the ADC will directly kill the tumor.
• the resulting release of tumor associated antigens from cells killed with the PBD dimer will trigger the immune system, which will be further enhanced by the use of a GITR agonist.
• GITR Glucocorticoid-induced TNFR-Related protein
• GITR ligation via its ligand GITRL stimulates both proliferation and function of both effector and regulatory CD4+ T cells. This promotes T-cell survival, and differentiation into effector cells, while abrogating suppression. Therefore it will be beneficial to target a FTP(+) tumor with the ADC, causing the antigenic cell death, while the GITR agonist induces a stronger, durable immune response.
• GITR agonists suitable for use as secondary agents in the present disclosure include:
• INCAGN1876 is an agonist antibody targeting the glucocorticoid-induced TNFR- related protein, or GITR. Discovered during a collaboration with Ludwig Cancer Research. INCAGN1876 is being co-developed with
• ⁇ VL comprising the sequence (CDR underline):
• ⁇ VH comprising the sequence (CDR underline):
• GWN323 an anti-GITR agonistic monoclonal antibody, which activates GITRs found on multiple types of T-cells. GWN323 is developed by Novartis
• GITR GITR agonistic monoclonal antibody
• MK-1248 has the same CDR as MK4166 (see Sukumar et al., Cancer Res. 2017) f) MK-4166, a humanized lgG1 anti-human glucocorticoid-induced tumor necrosis
• GITR GITR agonistic monoclonal antibody
• MoAb monoclonal antibody
• BMS-986156 An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody
• GITR polypeptide corresponds to Genbank accession no. AAD22635, version no. AAD22635.1 , record update date: Mar 10, 2010 09:42 PM.
• the nucleic acid encoding GITR polypeptide corresponds to Genbank accession no. AF125304, version no. AF125304.1 , record update date: Mar 10, 2010 09:42 PM.
• GITR polypeptide corresponds to Uniprot/Swiss-Prot accession No. Q9Y5U5.
• 0X40 (CD134; TNFRSF4) is a member of the TNFR super-family and is expressed by CD4 and CD8 T cells during antigen-specific priming. 0X40 expression is largely transient following TCR/CD3 cross-linking, and by the presence of inflammatory cytokines. In the absence of activating signals, relatively few mature T cell subsets express 0X40 at biologically relevant levels. Generating optimal“killer” CD8 T cell responses requires T cell receptor activation plus co-stimulation, which can be provided through ligation of 0X40 using a 0X40 agonist. This activating mechanism augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity. Therefore it will be beneficial to target a FTP(+) tumor with the ADC, causing the antigenic cell death, while the 0X40 agonist induces a stronger, durable immune response.
• the 0X40 agonist may be selected from the group consisting of an 0X40 agonist antibody, an OX40L agonist fragment, an 0X40 oligomeric receptor, and an 0X40 immunoadhesin.
• the 0X40 binding agonist is a trimeric OX40L-Fc protein.
• the 0X40 binding agonist is an OX40L agonist fragment comprising one or more extracellular domains of OX40L. In some embodiments, the 0X40 binding agonist is an 0X40 agonist antibody that binds human 0X40. In some embodiments, the 0X40 agonist antibody depletes cells that express human 0X40. In some embodiments, the 0X40 agonist antibody depletes cells that express human 0X40 in vitro. In some embodiments, the cells are CD4+ effector T cells. In some embodiments, the cells are Treg cells. In some embodiments, the depleting is by ADCC and/or phagocytosis. In some embodiments, the depleting is by ADCC.
• the 0X40 agonist antibody binds human 0X40 with an affinity of less than or equal to about 1 nM. In some embodiments, the 0X40 agonist antibody increases CD4+ effector T cell proliferation and/or increasing cytokine production by the CD4+ effector T cell as compared to proliferation and/or cytokine production prior to treatment with anti-human 0X40 agonist antibody. In some embodiments, the cytokine is gamma interferon. In some embodiments, the 0X40 agonist antibody increases memory T cell proliferation and/or increasing cytokine production by the memory cell. In some embodiments, the cytokine is gamma interferon.
• the 0X40 agonist antibody inhibits Treg function. In some embodiments, the 0X40 agonist antibody inhibits Treg suppression of effector T cell function. In some embodiments, effector T cell function is effector T cell proliferation and/or cytokine production. In some embodiments, the effector T cell is a CD4+ effector T cell. In some embodiments, the 0X40 agonist antibody increases 0X40 signal transduction in a target cell that expresses 0X40. In some embodiments, 0X40 signal transduction is detected by monitoring NFkB downstream signalling.
• 0X40 agonist means any chemical compound or biological molecule that stimulates an immune reaction through iactivation of 0X40 signalling.
• samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples treated with an inactive control molecule. Control samples are assigned a relative activity value of 100%.
• Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 20%.
• Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.
• an ADC which targets a first target protein (FTP) positive lymphomas and leukemias with 0X40 agonists is advantageous, because on the one hand the ADC will directly kill the FTP positive tumor cells, while on the other hand the 0X40 agonist will engage the patient’s own immune system to eliminate the cancer cells.
• FTP(+) tumor cells target negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of FTP(+) cells.
• the ADC will directly kill the tumor.
• the resulting release of tumor associated antigens from cells killed with the PBD dimer will trigger the immune system, which will be further enhanced by the use of a 0X40 agonist.
• Specific 0X40 agonists suitable for use as secondary agents in the present disclosure include:
• MEDI0562 (aka Tavolixizumab, Tavolimab)
• MOXR0916 also known as RG7888, Pogalizumab
• MOXR0916 also known as RG7888, Pogalizumab
• OX40mAb24 is a humanised version of 9B12.
• 9B12 is a murine IgGI, anti- 0X40 mAb directed against the extracellular domain of human 0X40 (CD134) (Weinberg, A.D., et al. J Immunother 29, 575-585 (2006)).
• Antibody sequences are disclosed in WO2016/179517 A1 :
• an antibody comprising the sequences:
• PF-04518600 (PF-8600) is an investigational, fully human, monoclonal antibody (mAb) that targets 0X40 protein
• 0X40 polypeptide corresponds to Genbank accession no. CAA53576, version no. CAA53576.1 , record update date: Feb 2, 2011 10:10 AM.
• the nucleic acid encoding 0X40 polypeptide corresponds to Genbank accession no. X75962, version no. X75962.1 , record update date: Feb 2, 201 1 10:10 AM.
• 0X40 polypeptide corresponds to Uniprot/Swiss-Prot accession No. P43489.
• CTLA4 (CD152) is expressed on activated T cells and serves as a co-inhibitor to keep T cell responses in check following CD28-mediated T cell activation.
• CTLA4 is believed to regulate the amplitude of the early activation of naive and memory T cells following TOR engagement and to be part of a central inhibitory pathway that affects both antitumor immunity and autoimmunity.
• CTLA4 is expressed exclusively on T cells, and the expression of its ligands CD80 (B7.1 ) and CD86 (B7.2), is largely restricted to antigen-presenting cells, T cells, and other immune mediating cells.
• Antagonistic anti-CTLA4 antibodies that block the CTLA4 signalling pathway have been reported to enhance T cell activation.
• ipilimumab was approved by the FDA in 2011 for the treatment of metastatic melanoma.
• Another anti-CTLA4 antibody, tremelimumab was tested in phase III trials for the treatment of advanced melanoma, but did not significantly increase the overall survival of patients compared to the standard of care (temozolomide or dacarbazine) at that time.
• CTLA4 agonist means any chemical compound or biological molecule that stimulates an immune reaction through inhibition of CTLA4 signalling.
• samples or assays comprising a given, e.g., protein, gene, cell, or organism, are treated with a potential activating or inhibiting agent and are compared to control samples treated with an inactive control molecule. Control samples are assigned a relative activity value of 100%.
• Inhibition is achieved when the activity value relative to the control is about 90% or less, typically 85% or less, more typically 80% or less, most typically 75% or less, generally 70% or less, more generally 65% or less, most generally 60% or less, typically 55% or less, usually 50% or less, more usually 45% or less, most usually 40% or less, preferably 35% or less, more preferably 30% or less, still more preferably 25% or less, and most preferably less than 20%.
• Activation is achieved when the activity value relative to the control is about 110%, generally at least 120%, more generally at least 140%, more generally at least 160%, often at least 180%, more often at least 2-fold, most often at least 2.5-fold, usually at least 5-fold, more usually at least 10-fold, preferably at least 20-fold, more preferably at least 40-fold, and most preferably over 40-fold higher.
• an ADC which targets a first target protein (FTP) positive lymphomas and leukemias with CTLA4 inhibitors is advantageous, because on the one hand, the ADC will directly kill the FTP positive tumor cells, while on the other hand the CTLA4 inhibitor will engage the patient’s own immune system to eliminate the cancer cells.
• FTP target protein
• target negative tumor cells in close proximity to FTP(+) tumor cells will potentially be killed by the bystander mechanism of the PBD-dimer released after cell kill of FTP(+) cells. Hence, the ADC will directly kill the tumor.
• TILs tumour infiltrating lymphocytes
• CTLA4 The major function of CTLA4 (CD152) is to regulate the amplitude of the early stages of T cell activation, and as such it counteracts the activity of the T cell co-stimulatory receptor, CD28, In the tumor microenvironment. Blockade of the CTLA4 pathway may therefore enhance enhancement of effector CD4+T cell activity, while it inhibits TReg cell-dependent immunosuppression. Therefore it will be beneficial to target a FTP(+) tumor with the ADC, causing the antigenic cell death, while the CTLA4 blockade induces a stronger immune, durable response.
• CTLA4 antagonists suitable for use as secondary agents in the present disclosure include:
• CTLA polypeptide corresponds to Genbank accession no. AAL07473, version no. AAL07473.1 , record update date: Mar 11 , 2010 01 :28 AM .
• the nucleic acid encoding CTLA4 polypeptide corresponds to Genbank accession no. AF414120, version no. AF414120.1 , record update date: Mar 1 1 , 2010 01 :28 AM .
• 0X40 polypeptide corresponds to Uniprot/Swiss-Prot accession No. P16410.
• the therapies described herein include those that induce or enhance a subject’s immune response by, for example, targeting immune regulatory cells such as Treg cells with a CD25- ADC.
• immune regulatory cells such as Treg cells with a CD25- ADC.
• the targeting of immune regulatory cells in this manner allows for a reduction in the negative regulation of the subject’s immune responses to an existing or newly presented antigen.
• the therapies decribed herein may therefore be advantageously combined with other therapies which induce or enhance a subject’s immune response.
• preclinical and clinical data indicate that combination of CD25-ADC administration with radiotherapy will lead to significant clinical benefits.
• the advantage is derived from the potential of radiotherapy to convert immunologically‘cold’ tumors into‘hot’ tumors by a combination of distinct mechanisms including: (a) increasing tumor immunogenicity via the upregulation of antigenic expression, antigen processing, major histocompatibility molecules, and costimulatory signals; (b) overcoming an
• immunosuppressive tumor microenvironment by shifting the cytokine balance in favor of immunostimulation (e.g. by increasing the production of immunostimulatory cytokines); (c) recruiting antigen-presenting and immune effector cells to the tumor microenvironment (see Ko et al., Ther Adv Med Oncol 2018, Vol. 10: 1-1 1 , DOI: 10.1 177/1758834018768240).
• the effect of this immunological conversion of tumours is then amplifies by the immune regulatory cell depletion resulting from CD25-ADC administration.
• CD25-ADCs decribed herein are administered in combination with radiotherapy.
• radiation therapy or “radiotherapy” may refer to the medical use of ionizing radiation as part of cancer treatment to control or eradicate malignant cells.
• Radiotherapy may be used for curative, adjuvant, or palliative treatment.
• Suitable types of radiotherapy include conventional external beam radiotherapy, stereotactic radiation therapy (e.g., Axesse, Cyberknife, Gamma Knife, Novalis, Primatom, Synergy, X-Knife,
• Intensity-Modulated Radiation Therapy e.g., proton therapy
• particle therapy e.g., proton therapy
• brachytherapy delivery of radioisotopes
• intraoperative radiotherapy Auger therapy
• VMAT Volumetric modulated arc therapy
• Virtual simulation 3-dimensional conformal radiation therapy, and intensity-modulated radiation therapy.
• radiatiotherapy uses high-energy radiation to shrink tumors and kill cancer cells.
• the radiation may be, for example, X-rays, gamma rays, or charged particles.
• Modes of cell killing through radiation include DNA damage either directly or by creating free radicals within cells that in turn damage DNA.
• Radiation may be delivered by a machine outside the body (external-beam radiation therapy), or may come from radioactive material placed in the body near cancer cells (internal radiation therapy, also called brachy therapy).
• internal radiation therapy also called brachy therapy
• radioactive substances such as radioactive iodine, are used which travel in the blood to kill cancer cells.
• the radiotherapy is administered in a regime designed to minimize any immunosuppressive effects of the radiation.
• a regime designed to minimize any immunosuppressive effects of the radiation For example, preclinical evidence indicates high radiation doses above 12-18 Gy result in an attenuation of tumor immunogenicity
• Radiation dosages may be fractionated and administered in sequence; for example, on consecutive days until the total desired radiation dose is delivered.
• the CD25-ADC may be administered before the radiotherapy, simultaneous with the radiotherapy, or after the radiotherapy.
• the CD25-ADC is administered after the radiotherapy, for example the same day or the day after the completion of a radiotherapy dose.
• the therapies described herein include those that induce or enhance a subject’s immune response.
• the therapies include treating a disorder by inducing or enhancing the immune response of a subject against an antigen associated with the disorder.
• the therapies described herein enhance or induce an immune response by targeting immune regulatory cells with an antibody conjugated, i.e. covalently attached by a linker, to a PBD drug moiety, i.e. toxin.
• a PBD drug moiety i.e. toxin.
• the antibody-drug conjugates (ADC) of the disclosure selectively deliver an effective dose of a cytotoxic agent to the targeted tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved.
• ADC antibody-drug conjugates
• the methods described herein may be used in combination with other immune response stimulating agents in order to further enhance and/or induce an immune response.
• This approach is expected to have utility in, for example, highly immunosuppressive circumstances that are not overcome through use of a single immunostimulating agnet / method.
• molcules such as CD3/DAA bi-specific T-cell engagers (BiTEs) function to direct cytotoxic T-cells’ cell-killing activity against target cells bearing a DAA.
• BiTEs therefore stimulate an immune reaction against DAA bearing cells (see Zimmerman et al., International Immunology, Volume 27, Issue 1 , January 2015, Pages 31-37).
• a well known example of a BiTE is Blinatumomab - a CD3/CD19 BiTE used to treat CD19+ve B-cell linage cancers such as CLL and ALL (see Robinson et al. Blood 2018 :blood-2018-02- 830992).
• the immune reaction stimulated by a BiTE may still be suppressed by, for example: (1 ) high levels of immune suppressive cells (see Ellerman, Methods, Volume 154, 1 February 2019, Pages 102-1 17), and/or (2) activation of immune regulatory cells by the BiTE itself (see Koristka et al. 2015, Oncoimmunology. 2015 Mar; 4(3): e994441 ).
• the methods for reducing the immune-suppressive activity of a population of immune regulatory cells described herein may be usefully combined with, for example, BiTEs to further enhance the immune response against DAA bearing target cells.
• Such a combination will have particular utility in patient populations where the efficacy of a first immune stimulatory agent/method (eg. BiTE) is inhibited ro reduced by the immune- suppressive activity of a population of CD25+ve immune regulatory cells such as Tregs.
• a first immune stimulatory agent/method eg. BiTE
• the therapies described herein enhance or induce an immune response by directly killing target cells through cytotoxic ADC binding to the target cells and/or, through a ‘bystander effect’, indirectly killing target cells in the proximity of cells that are directly bound by the cytotoxic ADC (see, for example, WO/2017/083468).
• the killing of target cells causes the release of target antigens,‘stranger signals’, and/or‘danger signals’ into the extracellular environment where they can interact with and stimulate a subject’s immune system (see, for example, Virgil EJC Schijns & Ed C Lavelle (201 1 ) Expert Review of Vaccines, 10:4, 539- 550).
• the present disclosure provides a method of inducing or enhancing an immune response in a subject, the method comprising the step of administering a CD25- ADC to the subject.
• the induction or enhancement of immune response may be due to the reduction in the immune-suppressive activity of an immune regulatory cell population, as defined herein.
• the present disclosure provides a method of treating or preventing a disorder a subject, wherein the disorder is characterized by a disorder-associated antigen (DAA), the method comprising administering a CD25-ADC to the subject.
• DAA disorder-associated antigen
• the CD25-ADC is administered in combination with a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• the DAA may be a protein, polypeptide, peptide, peptide mimetic, nucleic acid encoding a protein, polypeptide, peptide, peptide mimetic, sugar, oligiosaccharide, lipid, phospholipid, liposaccharide, or lipoprotein.
• the DAA is a cell-surface antigen, meaning that in its normal pathogenic context it is found on the surface of a cell or pathogen such that is accessible to cells and molecules of a subject’s immune system.
• a CD25-ADC as described herein for use in inducing or enhancing an immune response in a subject, or for use in treating or preventing a disorder a subject wherein the disorder is characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• Another aspect of the present disclosure provides the use of a CD25-ADC as described herein in the manufacture of a medicament for inducing or enhancing an immune response in a subject, or for treating or preventing a disorder a subject wherein the disorder is characterized by a disorder-associated antigen (DAA).
• DAA disorder-associated antigen
• DAA disorder-associated antigen
• proliferative disorder pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo.
• proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocyoma, osteoma), cancers (e.g.
• lung cancer small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), lymphomas, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis.
• Cancers of interest include, but are not limited to, leukemias and ovarian cancers.
• Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
• gastrointestinal including, e.g. bowel, colon
• breast mammary
• ovarian prostate
• liver hepatic
• kidney renal
• bladder pancreas
• brain and skin.
• Proliferative disorders of interest include, but are not limited to, Hodgkin’s and non-Hodgkin’s Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL) [Fielding A., Haematologica. 2010 Jan; 95(1 ): 8-12]
• DLBCL diffuse large B-cell lymphoma
• FL Mantle Cell lymphoma
• CLL chronic lymphatic lymphoma
• Proliferative disorders of particular interest include those associated with elevated numbers of regulatory immune cells, such as Treg cells. These include chronic lymphatic lymphoma (CLL), T-cell Acute Lymphoblastic Leukaemia (T-ALL), and B-cell non-Hodgkin’s Lymphoma, such as Acute Myeloid Leukaemia (AML) [Niedzwiecki et al., J.lmmun.R., Vol.2018, Artilce ID 1292404]
• CLL chronic lymphatic lymphoma
• T-ALL T-cell Acute Lymphoblastic Leukaemia
• B-cell non-Hodgkin’s Lymphoma such as Acute Myeloid Leukaemia (AML) [Niedzwiecki et al., J.lmmun.R., Vol.2018, Artilce ID 1292404]
• Classical Hodgkins lymphoma includes the subtypes nodular sclerosing, lymphocyte predominant, lymphocyte depleted and mixed cellularity.
• the Hodgkins lymphoma subtype may not be defined.
• the patients tested according to the methods here have Hodgkins lymphoma of the nodular sclerosing and mixed cellularity subtypes.
• the proliferative disease may be characterised by the presence of a neoplasm comprising both CD25+ve and CD25-ve cells.
• the proliferative disease may be characterised by the presence of a neoplasm composed of CD25-ve neoplastic cells, optionally wherein the CD25-ve neoplastic cells are associated with CD25+ve non-neoplastic cells such as CD25+ve Tregs.
• the target neoplasm or neoplastic cells may be all or part of a solid tumour.
• Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of CD25+ve neoplastic cells.
• Solid tumors may be neoplasms infiltrated with CD25+ve cells, such as CD25+ve Tregs; such solid tumours may lack expression of CD25 (that is, comprise or be composed of CD25-ve neoplastic cells).
• the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res. 2017 Jan;27(1 ):109-1 18).
• the solid tumour may be pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
• the solid tumour may be a tumour with low levels of infiltrating T-cells, such as infiltrating regulatory T-cells.
• the solid tumour may be a tumour that is not associated or infiltrated with CD25+ve cells, such as CD25+ve Tregs.
• the high / low / no infiltrating T-cell status of a tumour is determined by measuring the ratio of T-regulatory cells / T-effector using, for example, FACS analusis of T-cells in a sample.
• the level of infiltrating T-cells is determined to be ‘high’ if the ratio of T-regulatory cells / T-effector is at least 20. In some embodiments the level of infiltrating T-cells is determined to be‘low’ if the ratio of T-regulatory cells / T-effector is less than 20.
• the neoplasm or neoplastic cells may be all or part of an established tumour.
• An‘establised tumour’ as described herein may be, for example, a tumour such as a solid tumour diagnosed or identified in a naive subject.
• the naive subject is a subject that has not yet been treated to reduce the immune-suppressive activity of an immune regulatory cell population, as defined herein; for example; treated with an anti-CD25 antibody or a CD25-ADC. In some cases the naive subject is a subject that has not yet been treated with ADCx25, as defined herein.
• the neoplasm or neoplastic cells may be a circulating tumour or circulating tumour cells (CTC; Gupta et al. 2006, Cell. 127 (4): 679-95; Rack et al., 2014. Journal of the National Cancer Institute. 106 (5)).
• the CTCs may be, or comprise, metastatic cells (i.e. CTCs capable of establishing metastatic tumours in a subject).
• the therapies of the present disclosure may be used to treat various proliferative disorders.
• exemplary conditions or hyperproliferative disorders include benign or malignant tumors; leukemia, haematological, and lymphoid malignancies.
• Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune disorders and graft-versus-host disease (GVHD).
• GVHD graft-versus-host disease
• the disease or disorder to be treated is a hyperproliferative disease such as cancer.
• cancer to be treated herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g.
• lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
• lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer,
• the therapies of the present disclosure may be used to treat any proliferative disorder that is characterized by a tumor-associated antigen (TAA).
• TAA tumor-associated antigen
• a TAA is an antigen that is either: (1 ) expressed only on neoplastic cells, or (2) expressed at higher levels by neoplastic cells as compared to non-neoplastic (i.e. normal cells).
• a TAA will be an antigen present on the surface of a neoplastic cell.
• the TAA is selected from the group consisting of:
• BMPR1B bone morphogenetic protein receptor-type IB
• NP_001194 bone morphogenetic protein receptor, type IB /pid NP_001194.1.
• W02004/032842 Example IV
• W02003/042661 Claim 12
• W02003/016475 Claim 1
• WO2002/78524 Example 2
• W02002/99074 Claim 19; Page 127-129
• WO2002/86443 Claim 27; Pages 222, 393
• W02003/003906 Claim 10; Page 293
• WO2002/64798 Claim 33; Page 93-95
• W02000/14228 Claim 5; Page 133-136
• US2003/224454 Fig 3
• MPF MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin
• Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b)
• Serna 5b FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, 25 sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B)
• W02003/003984 (Claim 1 ); W02002/06339 (Claim 1 ; Page 50); W02001/88133 (Claim 1 ; Page 41-43, 48-58); W02003/054152 (Claim 20); W02003/101400 (Claim 1 1 ); Accession: 30 Q9P283; Genew; HGNC:10737
• PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene)
• Genbank record update date Mar 11 , 2010 02:26 AM Genbank accession no. AAP32295
• Genbank record update date Mar 11 , 2010 02:26 AM
• W02004/048938 (Example 2); W02004/040000 (Claim 151 ); W02003/087768 (Claim 1 );
• W02003/016494 (Fig 6); W02003/025138 (Claim 12; Page 144); W02001/98351 (Claim 1 ; Page 124-125); EP0522868 (Claim 8; Fig 2); W02001/77172 (Claim 1 ; Page 297-299); US2003/109676; US6518404 (Fig 3); US5773223 (Claim 1 a; Col 31-34); W02004/001004.
• Genbank record update date Mar 11 , 2010 01 :54 AM
• Genbank record update date Mar 11 , 2010 01 :54 AM
• W02003/104270 (Claim 1 1 ); W02003/104270 (Claim 16); US2004/005598 (Claim 22); W02003/042661 (Claim 12); US2003/060612 (Claim 12; Fig 10); WO2002/26822 (Claim 23; Fig 2); WO2002/16429 (Claim 12; Fig 10); Gl:22655488.
• TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation 5 channel, subfamily M, member 4)
• Genbank record update date Jun 29, 2012 11 :27 AM
• Genbank record update date Jun 29, 2012 1 1 :27 AM
• W02002/16413 (Claim 1 ; Page 94-95, 105); W02002/22808 (Claim 2; Fig 1 ); US5854399 (Example 2; Col 17-18); US5792616 (Fig 2); MIM:187395.
• CD21 CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792)
• CD79b (CD79B, CD79 , IGb (immunoglobulin-associated beta), B29)
• Genbank record update date Jun 26, 2012 01 :53 PM Genbank accession no. NP_000617
• Genbank record update date Jun 26, 2012 01 :53 PM
• FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 5 1a), SPAP1B, SPAP1C)
• W02003/089904 (Claim 9); W02003/016475 (Claim 1 ); US2003/1 18592; W02003/008537 (Claim 1 ); W02003/055439 (Claim 29; Fig 1A-B); W02003/025228 (Claim 37; Fig 5C);
• WO2002/13847 (Page 71 -74); W02002/14503 (Page 1 14-1 17); WO2001/53463 (Claim 2; Page 41 -46); W02001/41787 (Page 15); W02000/44899 (Claim 52; Fig 7); W02000/20579 (Claim 3; Fig 2); US5869445 (Claim 3; Col 31 -38); WO9630514 (Claim 2; Page 56-61 );
• EP1439393 (Claim 7); W02004/043361 (Claim 7); W02004/022709; W02001/00244 25 (Example 3; Fig 4); Accession: P04626; EMBL; M1 1767; AAA35808.1. EMBL; M1 1761 ; AAA35808.1
• an antibody comprising CDRs having overall at least 80% sequence identity to CDRs having amino acid sequences of SEQ ID NO:3 (CDR-H1 ), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:104 and/or SEQ ID NO:6 (CDR-L1 ), SEQ ID NO:7 (CDR-L2), and SEQ ID NO:8 (CDR-L3), wherein the anti- HER2 antibody or anti-HER2 binding fragment has reduced immunogenicity as compared to an antibody having a VH of SEQ ID NO:1 and a VL of SEQ ID NO:2.
• a purified antibody molecule that binds to HER2 comprising a all six CDR's from an antibody selected from the group consisting of BIIB71 F10 (SEQ ID NOs:1 1 , 13), BIIB69A09 (SEQ ID NOs:15, 17); BIIB67F10 (SEQ ID NOs:19, 21 ); BIIB67F1 1 (SEQ ID NOs:23, 25), BIIB66A12 (SEQ ID NOs:27, 29), BIIB66C01 (SEQ ID NOs:31 , 33), BIIB65C10 (SEQ ID NOs:35, 37), BIIB65H09 (SEQ ID NOs:39, 41 ) and BIIB65B03 (SEQ ID NOs:43, 45), or CDRs which are identical or which have no more than two alterations from said CDRs.
• Herceptin (Genentech) - US6,054,297; ATCC accession no. CRL-10463 (Genentech)
• an antibody comprising the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively
• an antibody comprising a light chain amino acid sequence selected from SEQ ID No. 15 and 23, and a heavy chain amino acid sequence selected from SEQ ID No. 16 and 24
• an antibody comprising the amino acid sequence in SEQ ID No. 23, or a deamidated and/or oxidized variant thereof.
• an antibody having a light chain variable domain comprising the hypervariable regions of SEQ ID NO: 1”.
• an antibody having a heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2.
• WO2002/86443 (Claim 27; Page 427); W02002/60317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541 ; AAA59915.1.
• EP1394274 (Example 1 1 ); US2004/005320 (Example 5); W02003/029262 (Page 74-75); W02003/002717 (Claim 2; Page 63); WO2002/22153 (Page 45-47); US2002/042366 (Page 20-21 ); W02001/46261 (Page 57-59); WO2001/46232 (Page 63-65); W098/37193 (Claim 1 ; Page 55-59); Accession: Q9UHF4; Q6UWA9; Q96SH8; EMBL; AF184971 ; AAF01320.1.
• EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5)
• W02003042661 (Claim 12); W0200053216 (Claim 1 ; Page 41 ); W02004065576 (Claim 1 ); W02004020583 (Claim 9); W02003004529 (Page 128-132); W0200053216 (Claim 1 ; Page 42); MIM:600997.
• W02002/102235 (Claim 13; Page 299); US2003/091580 (Example 2); W02002/10187 (Claim 6; Fig 10); W02001/94641 (Claim 12; Fig 7b); W02002/02624 (Claim 13; Fig 1A-1 B); US2002/034749 (Claim 54; Page 45-46); W02002/06317 (Example 2; Page 320-321 , Claim 34; Page 321-322); WO2002/71928 (Page 468-469); W02002/02587 (Example 1 ; Fig 1 ); W02001/40269 (Example 3; Pages 190-192); W02000/36107 (Example 2; Page 205-207); W02004/053079 (Claim 12); W02003/004989 (Claim 1 ); WO2002/71928 (Page 233-234, 452-453); WO 01/16318.
• PSCA Prostate stem cell antigen precursor
• Genbank record update date Feb 1 , 201 1 1 1 :25 AM
• Genbank record update date Feb 1 , 201 1 1 1 :25 AM
• Genbank record update date Mar 11 , 2010 02:24 AM
• Genbank record update date Mar 11 , 2010 02:24 AM
• AP14954 lipoma HMGIC fusion-partnerlike protein /pid AAP 14954.1 - Homo sapiens (human); W02003/054152 (Claim 20); W02003/000842 (Claim 1 ); W02003/023013 (Example 3, Claim 20); US2003/194704 (Claim 45); Gl:30102449;
• BAFF-R B cell -activating factor receptor, BLyS receptor 3, BR3
• BAFF receptor /pid NP_443177.1 - Homo sapiens: Thompson, J.S., et al Science 293 (5537), 2108-211 1 (2001 ); W02004/058309; W02004/01 1611 ; W02003/045422 (Example; Page 32-33); W02003/014294 (Claim 35; Fig 6B); W02003/035846 (Claim 70; Page 615- 616); WO2002/94852 (Col 136-137); WO2002/38766 25 (Claim 3; Page 133);
• CD22 B-cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814) Nucleotide

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cell Biology (AREA)
• Organic Chemistry (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Hematology (AREA)
• Oncology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biotechnology (AREA)
• Virology (AREA)
• Biomedical Technology (AREA)
• Developmental Biology & Embryology (AREA)
• Zoology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (13)

Applications Claiming Priority (6)

Publications (1)

Family

ID=66810758

Family Applications (1)

Country Status (13)

Cited By (9)

Families Citing this family (4)

Citations (144)

• 2019
  • 2019-05-22 CA CA3098103A patent/CA3098103A1/en active Pending
  • 2019-05-22 JP JP2020564541A patent/JP2021524449A/ja not_active Ceased
  • 2019-05-22 BR BR112020023846-5A patent/BR112020023846A2/pt not_active Application Discontinuation
  • 2019-05-22 CN CN201980034789.3A patent/CN113286616A/zh active Pending
  • 2019-05-22 US US17/057,486 patent/US20220111065A1/en not_active Abandoned
  • 2019-05-22 SG SG11202010469QA patent/SG11202010469QA/en unknown
  • 2019-05-22 EP EP19729452.3A patent/EP3796942A1/en not_active Withdrawn
  • 2019-05-22 AU AU2019272838A patent/AU2019272838A1/en not_active Abandoned
  • 2019-05-22 WO PCT/EP2019/063262 patent/WO2019224275A1/en not_active Ceased
  • 2019-05-22 MX MX2020012418A patent/MX2020012418A/es unknown
  • 2019-05-22 KR KR1020207037115A patent/KR20210016562A/ko not_active Ceased
• 2020
  • 2020-11-18 IL IL278819A patent/IL278819A/en unknown
  • 2020-11-19 PH PH12020500670A patent/PH12020500670A1/en unknown

Patent Citations (181)

Non-Patent Citations (3439)